December 02, 2022
Axios Pro Exclusive Content
Happy Friday, Health Techies! Claire here, with your digest of this week’s news.
But first, a peek inside GHO’s buy of Sapio Sciences.
1 big thing: GHO’s lab informatics play
Illustration: Gabriella Turrisi/Axios
GHO Capital Partners’ European footprint set it apart from other bidders vying for lab informatics player Sapio Sciences, the firm tells Claire.
Why it matters: Lab informatics needs a tech revamp, with most processes remaining paper-based as legacy systems continue to dominate the market. With GHO’s backing to scale it, Sapio may emerge as a formidable player.
Details: GHO declined to disclose deal terms but told Claire that Sapio is a “profitable company strongly positioned to address an international, high-growth market demanding a uniquely scalable SaaS model.”
How it works: Baltimore-based Sapio’s platform manages clinical and life sciences data for research and development laboratories.
- The company’s Laboratory Information Management Systems, or LIMS, enable researchers to track results, search for sample information, follow samples through various protocols and examine analytical results — all in one place.
What’s next: GHO’s European footprint will drive major growth for the company in the region, GHO says.
- GHO said it may “selectively look at strategic add-ons for Sapio” but said the firm is mostly focused on investments in R&D and continuing to expand its customer base.
Flashback: Sapio was founded in 2004 by CEO Kevin Cramer.
